OBJECTIVES: Pulmonary sarcomatoid carcinoma (PSC) is a rare malignant neoplasm that accounts for a small percentage of non-smallcell lung carcinoma (NSCLC). At least 10% of PSCs has a spindle and/or giant cell component, which is often associated with a poor prognosis. We reviewed the Surveillance, Epidemiology, and End Results (SEER) database for the clinicopathological characteristics and surgical outcomes of PSCs.
INTRODUCTION
Pulmonary sarcomatoid carcinoma (PSC) is a rare malignant neoplasm, accounting for less than 1% of all lung cancers [1] . It may contain both carcinomatous and sarcomatous components and is often associated with a poor prognosis [2, 3] . The World Health Organization (WHO) classification system recognizes 5 types of PSCs: pure spindle cell, pure giant cell, carcinosarcoma, pulmonary blastoma and pleomorphic carcinoma [2] . Although a diagnosis of PSC can be suggested on small biopsies and cytology specimens, a definitive diagnosis should only be made on the resected specimens [2] . There are little data from retrospective studies about these rare tumours. Controversy exists with regard to the prognostic significance of PSCs [4, 5] . Many studies are small case series with a focus mostly on pathological descriptions [4] [5] [6] [7] [8] [9] , with little clinical outcomes data. We reviewed a large national database for clinicopathological characteristics and surgical outcomes for this tumour.
METHODS

Data sources
The Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute (NCI) was queried retrospectively to identify PSCs among lung cancer patients based on inpatient status. †Presented at the 25th European Conference on General Thoracic Surgery, Innsbruck, Austria, 28-31 May 2017.
The Public Use version of data collected from the SEER 18 registries between 1973 and 2013 was used for this study. We included only patients with single primary tumour (sequence number = 0 or 1), as survival in patients with multiple primary tumours could not be ascribed to a single anatomical cancer site.
Study population and inclusion criteria
According to the International Classification of Diseases for Oncology, 3rd edition codes (ICD-1-O Codes), pleomorphic carcinoma (8022/3), spindle cell carcinoma (8032/3), giant cell carcinoma (8031/3), carcinosarcoma (8980/3) and pulmonary blastoma (8972/3) are grouped under the term PSC [2, 10] . Among our cohort, giant and spindle cell carcinoma represented (72.9%), pleomorphic carcinoma (13.4%), carcinosarcoma (11.5%) and pulmonary blastoma (2.2%) of the entire cohort. Data of patients for whom information was obtained solely from the autopsy or death certificate and information that lacked survival time were excluded.
Study variables
Available data in the SEER files that included variables, such as gender, age, race, year of diagnosis, histological subgroup, grade, stage with its components T, N and M stage, tumour size, surgical resection, survival months and vital status, and whether the patient was alive or dead at the last follow-up were retrieved. Patients who died in less than a month were coded as having a survival time of zero in the SEER registries. We assigned a survival time of 1.5 months according to a previously established and standard epidemiological convention [11] .
Survival and follow-up data
Overall survival (OS) is identified as the time ranging from the date of diagnosis until the date of death from any cause or the date of the last follow-up. The interquartile range (IQR) of the follow-up period among our cohort was 10-91 months with a median of 41 months. The median (IQRs) follow-up period in giant and spindle cell carcinomas was 33 (9-90) months, pleomorphic carcinoma was 42 (9-74) months, carcinosarcoma was 53 (20.25-101) months and pulmonary blastoma was 80 (20-135) months.
Statistical methods
The primary outcome was to identify the OS in PSCs in the whole group and in different stages of PSCs and histology using the Kaplan-Meier survival curves with log-rank test.
The secondary outcomes were to compare different clinicopathological parameters and survival data between PSCs and a contemporaneously treated group of non-small-cell lung carcinoma (NSCLC) cohorts. Subgroup analysis of our PSC cohort, which was represented by 2 historical periods of 20 years, early vs late (1994-2013), was conducted.
Continuous variables were presented as median and IQR and compared using the Mann-Whitney U-test. Categorical variables were reported as numbers (frequency percentages) and compared using the Pearson's v 2 test. Cox regression analysis was used to identify the factors predicting survival in both univariate and multivariate analyses.
Logistic regression analysis for predictors of node-positive disease was performed. A propensity score (PS)-matched analysis (including age as a continuous variable, gender, grade and stage) among surgically treated cases was done to compare OS in PSC patients versus other NSCLC patients. Matching was done 1 to 2 with the use of the nearest neighbour methods without replacement using 0.01 caliper width.
The Kaplan-Meier survival curves were done and compared using log-rank test, where a P-value of <0.05 was considered statistically significant. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated. Statistical analyses were conducted using IBM SPSS software (Released 2013; IBM SPSS Statistics for Windows, Version 22.0; IBM Corp., Armonk, NY, USA), PS-matching package version 3.03 and SPSS statistics R essentials.
RESULTS
Demographics and clinicopathological data
A total of 955 899 NSCLC patients were identified; of these, 4987 patients had PSC (0.52%). The majority were men (60.9%), and the median age was 68 years. In all, 11.4% of the PSC patients versus 11% in other NSCLC patients were Blacks (P < 0.001). High-grade tumours represented 97.2% of PSCs vs 61.9% of other NSCLCs (P < 0.001). Stage I represented 20.5% of PSCs vs other NSCLCs (24.2%, P < 0.001, Table 1 ). More advanced T stages (T3-4) were prevalent in PSCs (54.8%) vs other NSCLCs (45.5%, P < 0.001). Median tumour size was 5 (3.3-7.5) cm and 3.5 (2.3-5.4) cm in PSCs and other NSCLCs, respectively (P < 0.001). Significantly more patients with PSC had node-positive disease (49.7% vs 45.3% in other NSCLCs; P < 0.001) as well as M1 disease (44.3% vs 42.2% in NSCLCs; P < 0.001).
Among the PSCs, predictors of N + disease on multivariate analysis were advanced T stage (P < 0.001; Table 2 ). N + disease was evident in 52.3% of giant/spindle cell carcinoma, 49% in pleomorphic carcinoma, 38.5% of carcinosarcoma and 25.6% of pulmonary blastoma (P < 0.001). Surgery was done in 2011 patients (40.3%). Procedure was known in 1979 patients [local destruction (laser ablation, cautery or fulguration) in 1.2% of patients, sublobar resection in 14.1% of patients, lobe/bilobectomy in 1170 (59.1%) patients, pneumonectomy in 201 (10.2%) patients and resection/surgery NOS in 305 (15.4%) patients].
Subgroup analysis of the PSC patients revealed that late time period (1994-2013) has 3865 (77.5%) patients with median age of 70 (60-77) vs 63 (54-71) years in the early group (P < 0.001). This was reflected in the percentage of patients who underwent surgery (39.3 vs 48.1%). Regarding histology, pleomorphic carcinoma predominates in late years (13.9 vs 11.8%) with similar predomination of pulmonary blastoma (2.6 vs 0.8%; P < 0.001). There was no statistically significant difference regarding race, grade, stage or OS (P > 0.05).
Among 2011 (40.3%) patients who underwent surgery, subgroup analysis according to the two 20-year periods revealed that late time period (1994-2013) had 1505 (74.8%) patients with a median age of 67 (58-75) vs 60 (53-68) years in the early group (1973-1993; P < 0.001). Although the late time period group had older patients, they showed a better OS [median OS was 20 months (95% CI = 17.2-22.8) vs 13 months (95% CI = 10.6-15.4) for the early group, P = 0.013] that may be related to change in the histological subtypes with predominance of less aggressive types in the late time period. Pleomorphic carcinoma predominated in the late years (18.3 vs 9.5%) with similar predomination of pulmonary blastoma (5.8 vs 1.3%); however, carcinosarcoma decreased in the late years (15 vs 25.5%; P < 0.001). A higher number of nodes were sampled/dissected in the late years [median (IQR): 8 (4-13) vs 7 (4-11), P = 0.005] with lower use of radiation therapy in the late years (28.2 vs 38.1%, P < 0.001) and there was no statistically significant difference regarding race, grade or stage (P > 0.05).
Survival data
Among the whole PSC cohort, the median OS was 6 (95% CI 5.68-6.32) months with a 5-year OS of 15.5%.
Predictors of OS in Stages I/II PSC on multivariate analysis were advanced age (P < 0.001, HR = 1.03), male gender (P = 0.024, HR = 1.25), carcinosarcoma (P = 0.002, HR = 1.76), grade (P = 0.033, HR = 1.81), T stage (P = 004, HR = 1.75), N status (P = 0.001, HR = 1.90) and surgical resection (P < 0.001, HR = 0.58; Table 3 ). The median OS in pleomorphic carcinoma was 35 (95% CI 23.49-46.51) months, giant/spindle cell carcinoma was 22 (95% CI 17.97-26.03) months, pulmonary blastoma was 132 (95% CI 40.20-223.80) months and carcinosarcoma was 24 (95% CI 20.02-27.99) months (P < 0.001; Fig. 1 ). The 5-year OS was shortest in carcinosarcoma (17%) and longest in pulmonary blastoma (58.3%) (P < 0.001; Fig. 1 ). Median OS for N0 was 11 (95% CI 9.69-12.31) months, N1 was 7 (95% CI 5.97-8.03) vs 4 (95% CI 3.56-4.44) months and 2 (95% CI 1.27-2.73) months for N2 and N3, respectively.
An analysis of propensity-matched groups of surgically resected PSCs (n = 1069) and other NSCLCs (n = 2138) revealed worse OS among PSCs in all stages with a median and 5-year OS of 18 (95% CI 15.20-20.80) months and 30.5%, respectively, compared with 27 (95% CI 24.31-29.69) months and 32.5%, respectively, in the other NSCLCs (P = 0.009; Fig. 2 On analysing radiation therapy variable, we found a median and 5-year OS of 5 months (8%) for patients known to have received radiation therapy (n = 2060) vs 6 months (20.6%) for patients known to have not received it (P < 0.001).
For patients who did not undergo surgery, 1396 (48.8%) patients had radiotherapy with a median and 5-year OS of 4 months (3.4%) compared with 2 months (4.8%) patients who did not receive radiotherapy (P < 0.001).
Regarding sequencing of surgery and radiation therapy, we found that 576 (11.6%) patients known to have received adjuvant Variables with P-value < _0.10 in univariate analysis were involved in MVA. CI: confidence interval; HR: hazard ratio; MVA: multivariate analysis; OS: overall survival; PSC: pulmonary sarcomatoid carcinoma.
radiation therapy, 78 (1.6%) known to have received neoadjuvant radiation therapy and only 11 (0.4%) patients had both neoadjuvant and adjuvant radiation therapy. The median and 5-year OS for patients who had neoadjuvant or both neoadjuvant and adjuvant radiation therapy was 11 months (28.6%) vs 9 months (15.1%) for the adjuvant radiation therapy group (P = 0.018). No data regarding chemotherapy or targeted therapy were available in the public version of SEER database. To avoid heterogeneity among the long time frame of our study, we did a subgroup analysis from 2004 till the end of our study. We matched surgically resected PSC (n = 465) to a contemporaneously surgically resected NSCLC (n = 930) based on the same variables used before (age, gender, grade and stage) that revealed a median and 5-year OS of 24 months (37.9%) for PSC vs 42 months (42.7%) for other NSCLC (P = 0.001). A total of 656 (13.2%) patients were alive at the end of the study. The main causes of death among our cohort were death from lung cancer in 3574 (71.6%), heart disease in 171 (3.4%), chronic obstructive pulmonary disease in 84 (1.7%) and documented death from other causes of death in 61(1.2%) patients, whereas the remaining patients died from discrete causes, each represented <1% of the cohort.
DISCUSSION
This study has analysed a large cohort of PSC patients. We have leveraged the large SEER database to systematically study this rare cancer. Brambilla et al. [12] in 2001 reported that sarcomatoid histology is rare and found only in 0.1-0.4% of all patients with NSCLC. In this work, PSC accounted for 0.52% of NSCLCs. Of note, the gender distribution seen in this study (60%) is nearly similar to that reported by Martin et al. [3] (54%) but different from the proportion of men observed by others [7, 13] , who reported that more than 90% of their cohort were men.
In line with prior series, most of these tumours, when graded, were high grade [13, 14] . Prior series reported a short median survival between 8 and 19 months [3, 5, 8, 9, 13, [15] [16] [17] for patients with PSC, which is inferior to other NSCLCs. However, only some of the patients in these series underwent surgical resection. Other series reported no survival differences; however, their cohorts were small (<40 each) [4, 18] . Even in early-stage PSCs (Stage I/II), the OS in our study is only a median of 32 months. Similar to that reported by Martin et al. [3] , this study reported poor survival outcome in a PS-matched analysis of PSCs versus other NSCLCs is related to histology and is independent of other tumour features. In the series by Nakajima et al. [4] in which the authors included 37 and 647 patients of PSCs and NSCLC, respectively, there was no significant survival differences.
However, they did not perform multivariable analysis or stagematched comparisons. Also, Pelosi et al. [5] reported similar cancer-related survival among Stage I PSC versus other NSCLCs. Thirty-one PSC cases were included in their analysis; however, Stage III represented only 13%.
Similar to NSCLC patients, PSC patients with advanced age had worse survival [19] . Carcinosarcomas are clonal tumours [20, 21] developing through sarcomatoid change (rhabdomyosarcoma, chondrosarcoma and osteosarcoma) in a carcinoma (adenocarcinoma or squamous carcinoma) [20, 21] TP53 mutations are common in contrast to KRAS and EGFR. The presence of EGFR mutation is rare in carcinosarcoma; however, when present it is associated with better survival outcomes with the use of anti-EGFR treatment [22, 23] . Prior small case series have reported that PSC is resistant to conventional chemotherapy [24] , emphasizing the need to identify targetable genomic alterations.
In the SEER database study by Wright et al. [25] , carcinosarcomas of the bladder were reported to be more aggressive with poorer survival and higher recurrence when compared with other subtypes of bladder sarcomatoid carcinoma. The authors suggested separation of bladder carcinosarcomas as a separate category from sarcomatoid carcinoma [25] . This raises the question of whether or not we should also consider pulmonary carcinosarcomas as a separate entity from PSC as it was associated with the poorest survival among the remaining PSC histological subtypes.
The role of radiation therapy in PSC remains controversial and needs future randomized controlled trials as a prior series reported that irradiation causes sarcomatous or anaplastic changes in carcinoma [4, 26] . We found lower OS in patients who received radiation therapy, although only 1 month difference between both groups, but we are studying an already aggressive disease.
Strengths and limitations
The strength of this study is that it is the largest reported PSC series in the literature and utilizes a PS-matched analysis. The inherent limitation of the analysis is that it is retrospective, and our results must be tempered by the limitations of available information included in the SEER database. For example, little information exists with regard to the details of radiation and chemotherapy.
CONCLUSIONS PSC patients present with more advanced stage disease with worse survival compared to other NSCLC patients. While surgical resection conveys a survival advantage in PSC, this group represents a high-risk population for relapse and should be evaluated for novel adjuvant therapies.
